GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cessatech AS (XSAT:CESSA) » Definitions » Notes Receivable

Cessatech AS (XSAT:CESSA) Notes Receivable : kr0.00 Mil (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Cessatech AS Notes Receivable?

Cessatech AS's Notes Receivable for the quarter that ended in Mar. 2025 was kr0.00 Mil.


Cessatech AS Notes Receivable Historical Data

The historical data trend for Cessatech AS's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cessatech AS Notes Receivable Chart

Cessatech AS Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Notes Receivable
- - - - -

Cessatech AS Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Cessatech AS Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Cessatech AS Notes Receivable Related Terms

Thank you for viewing the detailed overview of Cessatech AS's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Cessatech AS Business Description

Traded in Other Exchanges
Address
Strandvejen 60, Hellerup, DNK, DK- 2900
Cessatech AS is a pharmaceutical company committed to developing and commercializing evidence-based medicines for children for the treatment of paediatric acute pain. Its product (CT001) is an analgesic nasal spray for the treatment of acute and planned painful procedures in children. Its other products CT002 which is a Non-invasive nasal spray and CT003 which is a local anaesthetic gel are in different stages development.

Cessatech AS Headlines

No Headlines